Lipella Pharmaceuticals regains Nasdaq equity compliance after $5.9M placement

LIPELLA PHARMACEUTICALS INC.

Final closing of Series B convertible preferred stock offering on March 12, 2025; net proceeds ~$5.9M.
Also issued warrants to purchase up to 72,000 Series B shares at $100/share on March 17, 2025; gross proceeds $9,000.
Stockholders' equity was ~$1.9M as of Dec 31, 2024; after offerings, company believes it meets Nasdaq's Stockholders' Equity Requirement.
Nasdaq continued listing is subject to compliance; company states it currently remains in compliance.

item 8.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001753926-25-000623
form_type: 8-K
ticker: LIPO
cik: 0001347242
company_name: LIPELLA PHARMACEUTICALS INC.
filed_at: 2025-04-14T23:59:59+00:00
discovered_at: 2026-05-14T18:02:48.041270+00:00
generated_at: 2026-05-23T15:22:18.438249+00:00
sec_items: ["8.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.75
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001753926-25-000623
json_url: https://secwatch.observer/filing/0001753926-25-000623.json
markdown_url: https://secwatch.observer/filing/0001753926-25-000623.md
text_url: https://secwatch.observer/filing/0001753926-25-000623.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1347242/000175392625000623/0001753926-25-000623-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1347242/000175392625000623/g084773_8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001753926-25-000623

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.